Chin Lee

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Synthesis, Characterization, and Morphology of Model Graft Copolymers with Trifunctional Branch Points

Samuel P. Gido, Chin Lee, Darrin J. Pochan et al. · Macromolecules · 1996 · 140 citations

Natural Sciences, Chemistry, Materials Science +17

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

David Isenberg, Richard Furie, Nicholas S. Jones et al. · Arthritis & Rheumatology · 2021 · 134 citations

Medicine, Pharmacology, Pharmacotherapy +16

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase <scp>II</scp> Trial

Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto et al. · Arthritis & Rheumatology · 2020 · 118 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Late Stages of Phase Separation in a Binary Polymer Blend Studied by Rheology, Optical and Electron Microscopy, and Solid State NMR

Ioannis S. Polios, Maria Soliman, Chin Lee et al. · Macromolecules · 1997 · 102 citations · Full text

Natural Sciences, Chemistry, Materials Science +17